GSK vs NVO

GSK plc and Novo Nordisk A/S, both Healthcare

Novo Nordisk A/S is the larger company at $171B against $101B. Over the past year GSK returned +18% against -34% for NVO. The RyuScore puts NVO ahead, 88 against 67 out of 100.

GSK plc and Novo Nordisk A/S compared on valuation, return and the RyuScore
FigureGSKNVO
Last close$46.91$38.58
Market cap$101B$171B
1-year return+18%-34%
5-year return+45%-16%
RyuScoresector-relative, 1–1067/10088/100

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

GSK plc

GSK overviewrevenue and segmentsvaluation

Novo Nordisk A/S

NVO overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or see the correlation.